Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end
stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative
complement pathway and familial forms for all types of MPGN have been reported suggesting
that genetic abnormalities may play a predisposing role to the disease. In recent case
reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the
membrane attack complex ,is a safe and effective therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research